Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered Entry - Hold Rating

Live News

As of April 23, 2026, 11:54 UTC, Johnson & Johnson (NYSE: JNJ) was featured as a top bullish pick on Jim Cramer’s *Mad Money* program, with Cramer announcing that his Charitable Trust had initiated a position in the stock during the ongoing sector-wide pullback. Cramer noted that pharma is currently deeply out of favor with market participants, who have rotated heavily into high-growth AI and cyclical industrial names so far this year, creating a rare opportunity to buy high-quality healthcare a Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntrySome investors find that using dashboards with aggregated market data helps streamline analysis. Instead of jumping between platforms, they can view multiple asset classes in one interface. This not only saves time but also highlights correlations that might otherwise go unnoticed.From a macroeconomic perspective, monitoring both domestic and global market indicators is crucial. Understanding the interrelation between equities, commodities, and currencies allows investors to anticipate potential volatility and make informed allocation decisions. A diversified approach often mitigates risks while maintaining exposure to high-growth opportunities.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntrySome traders prioritize speed during volatile periods. Quick access to data allows them to take advantage of short-lived opportunities.

Key Highlights

1. **Valuation Profile**: JNJ currently trades at 13.2x forward 12-month price-to-earnings (P/E), a 22% discount to its 5-year historical average of 16.9x, and an 18% discount to the large-cap pharma peer group average of 16.1x. The stock also offers a 3.1% annual dividend yield, with 59 consecutive years of dividend increases, earning it Dividend King status, one of only 48 U.S. public companies to hold the designation. 2. **Icotyde Catalyst**: Consensus sell-side estimates project Icotyde will Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryPredictive tools often serve as guidance rather than instruction. Investors interpret recommendations in the context of their own strategy and risk appetite.Scenario modeling helps assess the impact of market shocks. Investors can plan strategies for both favorable and adverse conditions.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryAccess to multiple indicators helps confirm signals and reduce false positives. Traders often look for alignment between different metrics before acting.

Expert Insights

Cramer’s bullish call on JNJ aligns with core portfolio construction principles he cited from his tenure at Goldman Sachs, noting that “assets do not appreciate in unison, and defensive exposure is critical to mitigating drawdowns in growth-heavy portfolios.” With a 5-year beta of 0.62, JNJ is 38% less volatile than the broader S&P 500, making it an ideal hedge for investors holding concentrated positions in high-beta AI and tech stocks that have led 2026 market gains. That said, investors should weigh material downside risks before initiating a position. JNJ’s top-selling immunology drug Stelara loses U.S. exclusivity in 2027, with consensus estimates projecting the loss of $2.1 billion in annual revenue by 2028 before Icotyde and other pipeline assets can offset the decline. Additionally, proposed U.S. drug pricing reforms could compress margins for JNJ’s top 10 selling products by an estimated 7% to 9% if passed in their current form. Consensus analyst ratings remain largely bullish on JNJ, with 18 of 24 covering analysts assigning a Buy or Strong Buy rating, and a weighted average 12-month price target of $187, implying 21% upside from JNJ’s April 23 closing price of $154.50. For investors seeking higher short-term upside, as noted in recent market analysis, select undervalued AI plays positioned to benefit from onshoring trends and Trump-era tariff policies may offer higher risk-adjusted returns, though these assets carry far higher volatility and drawdown risk than JNJ. Overall, JNJ represents a high-quality defensive play for long-term investors with moderate risk tolerance, and the current sector selloff offers a rare entry point to one of the U.S.’s most consistent operational performers. For growth-focused investors, a 5% to 10% portfolio allocation to JNJ can provide meaningful downside protection without sacrificing long-term total return potential, balancing exposure to high-growth segments that dominate current market momentum. (Word count: 1172) Disclosure: No holdings in JNJ or mentioned AI securities as of publication. Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntrySome traders rely on patterns derived from futures markets to inform equity trades. Futures often provide leading indicators for market direction.Market behavior is often influenced by both short-term noise and long-term fundamentals. Differentiating between temporary volatility and meaningful trends is essential for maintaining a disciplined trading approach.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryWhile data access has improved, interpretation remains crucial. Traders may observe similar metrics but draw different conclusions depending on their strategy, risk tolerance, and market experience. Developing analytical skills is as important as having access to data.